![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.813 |
Chemical and physical data | |
Formula | C25H29N9O3 |
Molar mass | 503.567 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. [1] Positive results were reported in Phase II clinical trials in humans, [2] but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013. [3]
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.813 |
Chemical and physical data | |
Formula | C25H29N9O3 |
Molar mass | 503.567 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. [1] Positive results were reported in Phase II clinical trials in humans, [2] but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013. [3]